CIK 0001653087 · Accelerated filer<br>Smaller reporting company
Alector, Inc.
Sign in to watch- Ticker
- ALEC
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 822933343
- Phone
- 415-231-5660
- Business address
- 131 OYSTER POINT BLVD., SUITE 600, SOUTH SAN FRANCISCO, CA, 94080
- Former names
- Alector LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $296,087
- in 3 filings
Net −$296,087. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 76 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-10-01 | King Robert Chief Development Officer | Grant or award · Employee Stock Option (right to buy) | +35,635 | 35,635 | ||
| 2021-10-01 | Rosenthal Arnon Chief Executive Officer | Grant or award · Employee Stock Option (right to buy) | +417,213 | 417,213 | ||
| 2021-09-23 | GAROFALO ELIZABETH A. Director | Grant or award · Stock Option (right to buy) | +33,235 | 33,235 | ||
| 2021-09-23 | Rosenthal Arnon Chief Executive Officer | Sale | −9,625 | $25.10 | $242K | 2,302,875 |
| 2021-09-22 | Rosenthal Arnon Chief Executive Officer | Sale | −94,717 | $25.29 | $2.4M | 2,317,783 |
| 2021-09-22 | Rosenthal Arnon Chief Executive Officer | Sale | −5,283 | $26.10 | $138K | 2,312,500 |
| 2021-09-21 | Rosenthal Arnon Chief Executive Officer | Sale | −91,538 | $26.07 | $2.4M | 2,420,962 |
| 2021-09-21 | Rosenthal Arnon Chief Executive Officer | Sale | −8,462 | $26.56 | $225K | 2,412,500 |
| 2021-09-20 | Rosenthal Arnon Chief Executive Officer | Sale | −91,954 | $25.76 | $2.4M | 2,520,546 |
| 2021-09-20 | Rosenthal Arnon Chief Executive Officer | Sale | −8,046 | $26.33 | $212K | 2,512,500 |
| 2021-09-10 | Yaffe Kristine Director | Option exercise | +2,000 | $18.10 | $36K | 2,000 |
| 2021-09-10 | Yaffe Kristine Director | Option exercise · Stock Option (right to buy) | −2,000 | 38,000 | ||
| 2021-08-09 | Paul Robert Chief Medical Officer | Option exercise | +9,691 | $8.16 | $79K | 244,010 |
| 2021-08-09 | Paul Robert Chief Medical Officer | Option exercise | +8,734 | $10.14 | $89K | 252,744 |
| 2021-08-09 | Paul Robert Chief Medical Officer | Option exercise | +4,525 | $17.15 | $78K | 257,269 |
| 2021-08-09 | Paul Robert Chief Medical Officer | Sale | −22,650 | $27.17 | $615K | 234,619 |
| 2021-08-09 | Paul Robert Chief Medical Officer | Sale | −300 | $27.79 | $8K | 234,319 |
| 2021-08-09 | Paul Robert Chief Medical Officer | Option exercise · Employee Stock Option (right to buy) | −9,691 | 81,000 | ||
| 2021-08-09 | Paul Robert Chief Medical Officer | Option exercise · Employee Stock Option (right to buy) | −8,734 | 31,250 | ||
| 2021-08-09 | Paul Robert Chief Medical Officer | Option exercise · Employee Stock Option (right to buy) | −4,525 | 84,450 |
Page 16 of 23 · 454 trades